Crossmark

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Crossref DOI link: https://doi.org/10.1186/s12885-019-5314-0

Published Online: 2019-01-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Borchert, Sabrina https://orcid.org/0000-0002-0447-3206
Wessolly, Michael

Schmeller, Jan

Mairinger, Elena

Kollmeier, Jens

Hager, Thomas

Mairinger, Thomas

Herold, Thomas

Christoph, Daniel C.

Walter, Robert F. H.

Eberhardt, Wilfried E. E.

Plönes, Till

Wohlschlaeger, Jeremias

Aigner, Clemens

Schmid, Kurt Werner

Mairinger, Fabian D.
License Information

Text and Data Mining valid from 2019-01-30
More Information

Article History

Received: 2 July 2018

Accepted: 22 January 2019

First Online: 30 January 2019

Ethics approval and consent to participate

: The study conforms to the principles outlined in the declaration of Helsinki and was approved by the institutional review board (Ethics Committee of the Medical Faculty of the University Duisburg-Essen), protocol no.: 14–5775-BO. Due to the ethics approval, a patients’ informed consent has not been obtained.

: Not applicable.

: All authors have read and approved the manuscript and are aware of the submission. The authors declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below